Congratulations!

Farmasino 's strategic investment shareholder Novezan was listed on the Science and Technology Innovation Board!

The total market capitalization exceeds 37 billion!

On the morning of November 15, 2021, Nanjing Novezan Biotechnology Co., Ltd., a strategic investment shareholder of Farmasino, was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Stock abbreviation: Novezan Stock code: 688105.

Founded in 2012, Nanjing Novezan Biotechnology Co., Ltd. is a biotechnology enterprise focusing on enzymes, antigens, antibodies and other functional proteins and polymer organic materials for technology research and development and product development, relying on the key common technology platform independently established, has entered the field of biological reagents, in vitro diagnostic business, and is conducting the research and development of antibody drugs, is one of the few domestic R & D innovative enterprises with independent and controllable upstream technology development capabilities and terminal product production capacity.

At the listing ceremony, Cao Lin, chairman of Novazan said: Today, for us Novozan, it has a different meaning. For the arrival of this day, we have traveled through thick and thin for nearly 10 years, writing the development history of Novezan with sweat and tears. In the past, there was the perseverance of Novezan people and the care and support of many partners.

Farmasino Co., Ltd. is a member of Jiangsu Huihong International Group (stock code: 600981), one of China's top 500 companies, mainly engaged in pharmaceutical internationalization business, and its products are sold in more than 100 countries and regions around the world. With an annual export volume of nearly 200 million US dollars and annual sales of more than 1 billion yuan, the company has been awarded the "Top 10 Export Enterprises of Western Patent Medicine" by the China Medical Insurance Chamber of Commerce for 9 consecutive years and among the "Top 100 International Enterprises of Chinese Medicine" for 6 consecutive years. In 2017, the company was successfully elected as the vice president unit of China Chamber of Commerce for Import and Export of Medicines and Health Products.

In the first half of 2021, Farmasino introduced Nanjing Novezan Biotechnology Co., Ltd. as a strategic investor, and will carry out comprehensive cooperation with it in the broader field of pharmaceutical R&D, and form a joint force through the integration of high-quality resources to continuously push the R&D level of Kaiyuan Pharmaceutical to a higher platform, push its business scope to a broader market, and strive to become an international pharmaceutical company integrating R&D, production and sales.